Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies
US11186642B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Feb 22, 2017 |
| Grant date | Nov 30, 2021 |
| Priority date | — |
| Expiry date | Feb 22, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/50
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.